NRG Oncology (NRG) is a newly constituted National Clinical Trials Network (NCTN) group created through the coordinated efforts and scientific merger of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The NRG Oncology Biospecimen Bank (NRG-BB) will be formed from the three legacy biospecimen resources of the RTOG, GOG and NSABP into a single repository for all biospecimens collected as part of NRG Oncology clinical trials. NRG Oncology and the NCI have agreed to enroll up to 5,099 patients per year in future NCI-funded NRG-sponsored cancer clinical trials. We will collect, process and manage biospecimens from patients enrolled in Phase II & III clinical treatment trials to maintain an accurate and effective repository of tumor and normal tissues with associated clinical, epidemiologic, and descriptive biospecimen information, for use in trial-related activities and future translational science projects. The NRG-BB will maximize the quality and quantity of biospecimens and their derivatives through the utilization of standardized and optimal preservation, storage, quality assurance and distribution methods. We will market and distribute de-identified samples in a standardized and equitable manner to all qualified investigators both within and outside NRG Oncology by utilizing Biospecimen IT Navigator and NCTN Biospecimen front door services. Working with the biobanks from other NCTN groups and the Group Banking Committee of the NCI, we will harmonize biospecimen activities and processes. Finally, we will develop distributed infrastructure to support and/or perform innovative genomic analyses for patient assignment to multi-arm targeted therapy trials conducted by NRG Oncology. Robust informatics is required to allow translational scientists to know what is available within the NRG-BB and to equitably distribute biospecimens to the translational science community both within and outside NRG Oncology. We have anticipated this need by already harmonizing and consolidating our IT resources using a common Specimen Tracking and Reporting System (STARS) bioinformatics platform. This adoption of a common IT platform across the 3 legacy biospecimen banks has permitted an improved service level for the group, interoperability and freely exchangeable data with our NRG-BB partners and opportunities to enhance our links with the SDMC. Moreover, this new platform has permitted better external linkages with the Group Banking Committee, the NCI and with the Navigator and Front Door project.

Public Health Relevance

The collection, management and distribution of high quality and well annotated biospecimens associated with NRG clinical trials data will lead to translational studies for validating biomarkers of tumor prognosis and prediction of response to therapy, ultimately leading to improved treatment of cancer patients. These activities will support improved quality of biospecimens and expanded access for translational scientists, thus leading to better quality research and identifying appropriate patients for personalized approaches to improved cancer care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Makhlouf, Hala
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Nrg Oncology Foundation, Inc.
United States
Zip Code
Kim, S Rim; Song, Nan; Yothers, Greg et al. (2018) Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). Br J Cancer 118:629-633
Lawrence, Yaacov R; Moughan, Jennifer; Magliocco, Anthony M et al. (2018) Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer 124:491-498
Geyer Jr, Charles E; Tang, Gong; Mamounas, Eleftherios P et al. (2018) 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer 4:37
Bell, Erica H; Zhang, Peixin; Fisher, Barbara J et al. (2018) Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol 4:1405-1409
Ablain, Julien; Xu, Mengshu; Rothschild, Harriet et al. (2018) Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. Science 362:1055-1060
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Al-Hallaq, Hania A; Chmura, Steven J; Salama, Joseph K et al. (2017) Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases. Int J Radiat Oncol Biol Phys 97:155-163
van den Bent, Martin J; Baumert, Brigitta; Erridge, Sara C et al. (2017) Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 390:1645-1653
McCourt, Carolyn K; Deng, Wei; Dizon, Don S et al. (2017) A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 144:101-106
Ahsen, Mehmet Eren; Boren, Todd P; Singh, Nitin K et al. (2017) Sparse feature selection for classification and prediction of metastasis in endometrial cancer. BMC Genomics 18:233

Showing the most recent 10 out of 60 publications